Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for IDEAYA Biosciences's Debt-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDYA vs ARQT, NAMS, ALMS: Debt-to-Asset Comparison
For the Biotechnology subindustry, IDEAYA Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences Debt-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's Debt-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEAYA Biosciences (IDYA) has a Debt-to-Asset of 0.02 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on IDEAYA Biosciences and its competitors.
Is IDEAYA Biosciences' Debt-to-Asset too high?
IDEAYA Biosciences' current Debt-to-Asset is 0.02. Overall, IDEAYA Biosciences has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Debt-to-Asset compare to ARQT and NAMS?
IDEAYA Biosciences' Debt-to-Asset of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on IDEAYA Biosciences and its competitors. IDEAYA Biosciences's current Debt-to-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $237.94, compared to a current price of $36.30 — trading 84.7% below its estimated fair value. The current Debt-to-Asset is 0.02. IDEAYA Biosciences' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Debt-to-Asset is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (IDYA) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of $36.30 is trading 84.7% below its estimated GF Value™ of $237.94.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for IDYA:
Debt-to-Asset: 0.02
GF Value™: $237.94 vs. price of $36.30 (84.7% below fair value)
No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
48GF Score
Get the complete analysis for IDYA
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDYA has been successfully added to your 
